The outcome of relapsed childhood acute lymphoblastic leukemia after allogeneic hematopoietic stem‐cell transplantations: A single‐center experience

• Published in: Clinical transplantation Vol. 38; no. 5; pp. e15366 - n/a
• Main Authors: Aygüneş, Utku, Karagün, Barbaros Şahin, Şaşmaz, Ilgen, Antmen, Ali Bülent
• Format: Journal Article
• Language: English
• Published: Denmark 01-05-2024
• Subjects: acute lymphoblastic leukemia; Adolescent; Child; Child, Preschool; children; Female; Follow-Up Studies; Graft vs Host Disease - etiology; Hematopoietic Stem Cell Transplantation; Humans; Infant; Male; Neoplasm Recurrence, Local - pathology; Neoplasm Recurrence, Local - therapy; Precursor Cell Lymphoblastic Leukemia-Lymphoma - mortality; Precursor Cell Lymphoblastic Leukemia-Lymphoma - therapy; Prognosis; Recurrence; Retrospective Studies; Risk Factors; Salvage Therapy; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; hematopoietic stem cell transplantation; acute lymphoblastic leukemia; children
• ISSN: 0902-0063; 1399-0012; 1399-0012
• DOI: 10.1111/ctr.15366

In children with high‐risk childhood acute leukemia who undergo allogeneic hematopoietic stem‐cell transplantation (allo‐HSCT), relapse is still the leading cause of treatment failure. The prognosis is poor, yet prospective studies have only limited data on risk factors and outcomes. We aimed to understand the outcomes and prognostic factors for patients with acute lymphoblastic leukemia (ALL) who relapsed following allo‐HSCT. We analyzed retrospectively 46 children with childhood acute lymphoblastic leukemia who had relapsed after receiving their first alloHSCT. All these patients received salvage chemotherapy which consisted of fludarabine, cytarabine, and idarubicin before performing a second alloHSCT. The median follow‐up of the 46 patients after the first transplantation was 366 days. The median time from first allo‐HSCT to relapse was 278.4 ± 238.4 days. Forty‐six patients received salvage chemotherapy before the second alloHSCT, and CR was achieved in 32 of 46 patients. However, only 17 (37%) of 46 patients received a second allo‐HSCT, and 15 of 46 patients died from disease progression, infections, and bleeding. Twelve patients are still alive after the second allo‐HSCT. Two‐year overall survival (OS) was 38.9%. Local therapy was given to 10 (21.8%) patients, either as part of systemic therapy or alone. In multivariate analyses, the time of relapse and curative salvage therapy with a second allo‐HSCT were identified as significant prognostic factors for OS. Children with leukemia who had relapsed after the first allo‐HSCT received salvage chemotherapy. Our statistical analysis showed that the second HSCT could be beneficial for outcomes if patients relapsed beyond 180 days of the first allo‐HSCT.